Published in Exp Diabetes Res on February 03, 2010
Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction. Diabetes Metab Res Rev (2010) 1.21
Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions. Neurogastroenterol Motil (2014) 1.09
Repeated monitoring of corneal nerves by confocal microscopy as an index of peripheral neuropathy in type-1 diabetic rodents and the effects of topical insulin. J Peripher Nerv Syst (2013) 1.04
An overview of animal models of pain: disease models and outcome measures. J Pain (2013) 1.02
The role of long chain fatty acids and their epoxide metabolites in nociceptive signaling. Prostaglandins Other Lipid Mediat (2014) 0.98
Phenotyping animal models of diabetic neuropathy: a consensus statement of the diabetic neuropathy study group of the EASD (Neurodiab). J Peripher Nerv Syst (2014) 0.89
New function for an old enzyme: NEP deficient mice develop late-onset obesity. PLoS One (2010) 0.88
Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice. Neuropharmacology (2010) 0.87
Exercise-mediated improvements in painful neuropathy associated with prediabetes in mice. Pain (2013) 0.86
Effects of melatonin on biochemical factors and food and water consumption in diabetic rats. Adv Biomed Res (2014) 0.85
Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy. J Pain (2014) 0.85
Rab7 silencing prevents μ-opioid receptor lysosomal targeting and rescues opioid responsiveness to strengthen diabetic neuropathic pain therapy. Diabetes (2012) 0.84
Angiotensin II-NADPH oxidase-derived superoxide mediates diabetes-attenuated cell excitability of aortic baroreceptor neurons. Am J Physiol Cell Physiol (2011) 0.81
Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications. Exp Diabetes Res (2011) 0.81
Effects of diet-induced obesity on motivation and pain behavior in an operant assay. Neuroscience (2013) 0.81
Effect of Inhibition of Angiotensin-Converting Enzyme and/or Neutral Endopeptidase on Neuropathy in High-Fat-Fed C57Bl/6J Mice. J Obes (2012) 0.80
Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1. J Alzheimers Dis (2016) 0.79
Neprilysin deficiency protects against fat-induced insulin secretory dysfunction by maintaining calcium influx. Diabetes (2013) 0.79
Berberine ameliorates cold and mechanical allodynia in a rat model of diabetic neuropathy. J Med Food (2013) 0.79
Clock genes and behavioral responses to light are altered in a mouse model of diabetic retinopathy. PLoS One (2014) 0.78
Epoxy fatty acids mediate analgesia in murine diabetic neuropathy. Eur J Pain (2016) 0.77
Peripheral Neuropathy in Mouse Models of Diabetes. Curr Protoc Mouse Biol (2016) 0.76
Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels. Diabetologia (2016) 0.75
Spinal Disinhibition in Experimental and Clinical Painful Diabetic Neuropathy. Diabetes (2017) 0.75
Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care (2005) 7.81
The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology (2003) 3.60
Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care (2001) 2.53
High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition. Diabetes (2007) 1.85
Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve (2001) 1.85
Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes (2004) 1.79
Neutral endopeptidase modulation of septic shock. J Exp Med (1995) 1.53
Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms. Muscle Nerve (2007) 1.44
Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve. Int J Exp Diabetes Res (2000) 1.40
Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes (1997) 1.34
Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats. Am J Physiol Endocrinol Metab (2005) 1.32
Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice. Neurosci Lett (2008) 1.31
The control of microvascular permeability and blood pressure by neutral endopeptidase. Nat Med (1997) 1.31
Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain (1996) 1.27
An immunohistochemical study of endopeptidase-24.11 ("enkephalinase") in the pig nervous system. Neuroscience (1986) 1.24
Impaired glucose tolerance and neuropathy. Neurologist (2008) 1.19
The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res (2003) 1.16
Direct role of streptozotocin in inducing thermal hyperalgesia by enhanced expression of transient receptor potential vanilloid 1 in sensory neurons. Mol Pharmacol (2007) 1.14
Small fiber neuropathy is associated with the metabolic syndrome. Metab Syndr Relat Disord (2005) 1.14
Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse. Diabetes Obes Metab (2007) 1.12
The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy. Curr Drug Targets (2008) 1.11
ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes (2006) 1.10
Acetylcholine-induced arteriolar dilation is reduced in streptozotocin-induced diabetic rats with motor nerve dysfunction. Br J Pharmacol (1999) 1.10
Treatment of streptozotocin-induced diabetic rats with AVE7688, a vasopeptidase inhibitor: effect on vascular and neural disease. Diabetes (2007) 1.09
Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats. Cardiovasc Res (2003) 1.07
Neutral endopeptidase inhibition in diabetic wound repair. Wound Repair Regen (2002) 1.04
Fatty acids and glucose increase neutral endopeptidase activity in human microvascular endothelial cells. Shock (2003) 1.03
Changes in endoneurial blood flow, motor nerve conduction velocity and vascular relaxation of epineurial arterioles of the sciatic nerve in ZDF-obese diabetic rats. Diabetes Metab Res Rev (2002) 1.00
Platelet aggregation and coagulation in the pathogenesis of diabetic retinopathy in rats. Diabetes (1981) 0.99
Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction. Diabetes Obes Metab (2008) 0.98
Neutral endopeptidase activity is increased in the skin of subjects with diabetic ulcers. J Invest Dermatol (2002) 0.96
Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels. Eur J Pharmacol (1998) 0.96
Emerging treatments for hypertension: potential role for vasopeptidase inhibition. Am J Hypertens (1999) 0.95
Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats. Am J Hypertens (2001) 0.94
Inhibition of neutral endopeptidase (NEP) facilitates neurogenic inflammation. Exp Neurol (2005) 0.93
Neutral endopeptidase expression in mesangial cells. J Renin Angiotensin Aldosterone Syst (2003) 0.93
Distribution of neutral endopeptidase activity along the rat and rabbit nephron. Pharmacology (1999) 0.92
Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition. Diabetologia (2005) 0.92
Treatment of diabetic polyneuropathy: Update 2006. Ann N Y Acad Sci (2006) 0.92
Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase. Neurobiol Dis (2008) 0.91
Evidence for functional endothelin-converting enzyme activity in isolated rat basilar artery: effect of inhibitors. J Cardiovasc Pharmacol (1998) 0.91
The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy. Diabetologia (2003) 0.91
Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent. Br J Pharmacol (2004) 0.91
Induction of neutral endopeptidase (NEP) activity of SK-N-SH cells by natural compounds from green tea. J Pharm Pharmacol (2006) 0.91
Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure. Heart Rhythm (2005) 0.90
Central and peripheral nervous system complications. Diabetes (1982) 0.88
Diabetes mellitus and the sensory neuron. J Neuropathol Exp Neurol (2004) 0.88
Neutral endopeptidase expression and distribution in human skin and wounds. J Invest Dermatol (1999) 0.88
Neutral endopeptidase knockout induces hyperalgesia in a model of visceral pain, an effect related to bradykinin and nitric oxide. J Mol Neurosci (2002) 0.87
Effects of combined neutral endopeptidase 24-11 and angiotensin-converting enzyme inhibition on femoral vascular conductance in streptozotocin-induced diabetic rats. Br J Pharmacol (2000) 0.87
Therapy insight: neurological complications of prediabetes. Nat Clin Pract Neurol (2006) 0.86
Management of painful diabetic neuropathy. Expert Opin Pharmacother (2008) 0.85
Expression of endopeptidase-24.11 (common acute lymphoblastic leukaemia antigen CD10) in the sciatic nerve of the adult rat after lesion and during regeneration. Eur J Neurosci (1995) 0.85
Nerve growth factor (NGF) restores depletions of calcitonin gene-related peptide and substance P in sensory neurons from diabetic mice in vitro. J Neurol Sci (1994) 0.84
Bradykinin and matrix metalloproteinases are involved the structural alterations of rat small resistance arteries with inhibition of ACE and NEP. J Hypertens (2004) 0.83
Signal pathway involved in increased expression of neutral endopeptidase 24.11 by gonadotropin releasing hormone in choriocarcinoma cells. Placenta (2004) 0.82
Vascular neutral endopeptidase inhibition improves endothelial function and reduces intimal hyperplasia. Cardiovasc Res (2006) 0.79
Localization and regulation of renal Na+/myo-inositol cotransporter in diabetic rats. Kidney Int (1996) 0.76
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol (2004) 5.80
A critical role for eosinophils in allergic airways remodeling. Science (2004) 5.53
Arthritis critically dependent on innate immune system players. Immunity (2002) 5.31
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature (2009) 4.03
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev (2009) 3.65
Functional roles for C5a receptors in sepsis. Nat Med (2008) 3.33
Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci U S A (2009) 2.76
Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J Neurochem (2003) 2.42
The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci U S A (2002) 2.24
C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity (2005) 2.24
Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J Exp Med (2005) 2.23
Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med (2002) 2.17
A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest (2006) 2.15
The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections. Immunity (2008) 2.13
Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest (2004) 2.10
Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology (2008) 1.98
Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza A virus infection in mice. J Leukoc Biol (2004) 1.92
C5L2, a nonsignaling C5A binding protein. Biochemistry (2003) 1.90
An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J Biol Chem (2005) 1.89
Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules. Int Immunol (2004) 1.85
C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol (2009) 1.85
CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J Immunol (2007) 1.83
Early granuloma formation after aerosol Mycobacterium tuberculosis infection is regulated by neutrophils via CXCR3-signaling chemokines. Eur J Immunol (2003) 1.74
The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem (2009) 1.73
CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J Clin Invest (2002) 1.73
Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J (2006) 1.70
Both CXCR3 and CXCL10/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus. J Immunol (2006) 1.70
Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci (2004) 1.65
CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. J Immunol (2008) 1.61
Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/- mice with experimental autoimmune encephalomyelitis. J Immunol (2006) 1.59
CXCR3-dependent microglial recruitment is essential for dendrite loss after brain lesion. J Neurosci (2004) 1.57
C5a initiates the inflammatory cascade in immune complex peritonitis. J Immunol (2004) 1.57
Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes (2003) 1.50
Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol (2003) 1.46
Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med (2005) 1.45
Chemokine gene expression during fatal murine cerebral malaria and protection due to CXCR3 deficiency. J Immunol (2008) 1.42
NF-M is an essential target for the myelin-directed "outside-in" signaling cascade that mediates radial axonal growth. J Cell Biol (2003) 1.41
Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J Exp Med (2002) 1.41
Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation (2005) 1.40
Reduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch. Pain (2004) 1.40
Delayed and deficient dermal maturation in mice lacking the CXCR3 ELR-negative CXC chemokine receptor. Am J Pathol (2007) 1.38
C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol (2013) 1.38
Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci (2009) 1.37
The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol (2004) 1.37
Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction. Blood (2007) 1.37
C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. Eur J Immunol (2010) 1.34
Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation. Blood (2008) 1.33
Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice. Neurosci Lett (2008) 1.31
Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochem (2008) 1.29
CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin. Am J Respir Crit Care Med (2012) 1.28
Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J Immunol (2010) 1.24
Dendritic cell function in allostimulation is modulated by C5aR signaling. J Immunol (2009) 1.24
Blockade of CXCR3 receptor:ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome. J Immunol (2004) 1.24
Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation (2008) 1.22
Substance P signaling mediates BMP-dependent heterotopic ossification. J Cell Biochem (2011) 1.21
Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction. Diabetes Metab Res Rev (2010) 1.21
Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region. J Biol Chem (2002) 1.20
CXCR3-/- mice mount an efficient Th1 response but fail to control Leishmania major infection. Eur J Immunol (2005) 1.20
IFN-gamma acts on T cells to induce NK cell mobilization and accumulation in target organs. J Immunol (2006) 1.19
Allodynia and hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal potassium-chloride co-transporters. Pain (2008) 1.18
Mitochondrial respiratory chain dysfunction in dorsal root ganglia of streptozotocin-induced diabetic rats and its correction by insulin treatment. Diabetes (2010) 1.17
A critical role for C5L2 in the pathogenesis of experimental allergic asthma. J Immunol (2010) 1.16
The regulation of liver cell survival by complement. J Immunol (2009) 1.15
Secondary lymphoid tissue chemokine (CCL21) activates CXCR3 to trigger a Cl- current and chemotaxis in murine microglia. J Immunol (2002) 1.15
Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology. Neurosci Res (2002) 1.14
3BP2 deficiency impairs the response of B cells, but not T cells, to antigen receptor ligation. Mol Cell Biol (2006) 1.13
Efficient T-cell surveillance of the CNS requires expression of the CXC chemokine receptor 3. J Neurosci (2004) 1.13
Chemokine receptor deficiency is associated with increased chemokine expression in the peripheral and central nervous systems and increased resistance to herpetic encephalitis. J Neuroimmunol (2005) 1.12
CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol (2006) 1.12
Gene replacement in mice reveals that the heavily phosphorylated tail of neurofilament heavy subunit does not affect axonal caliber or the transit of cargoes in slow axonal transport. J Cell Biol (2002) 1.11
Attenuation of acute lung inflammation induced by cigarette smoke in CXCR3 knockout mice. Respir Res (2008) 1.10
CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J Am Soc Nephrol (2008) 1.08
MCP-1 expression in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci (2002) 1.08
CXCR3 ligands contribute to Th1-induced inflammation but not to homing of Th1 cells into the lung. Exp Lung Res (2008) 1.06
Mast cell protease 5 mediates ischemia-reperfusion injury of mouse skeletal muscle. J Immunol (2005) 1.06